Advertisement

Topics

Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency

2016-11-30 15:45:22 | BioPortfolio

Summary

To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency, as well as to study the feasibility of extending the dosing intervals (once per two weeks) of PEG Somatropin Injection.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Growth Hormone Deficiency

Intervention

Jintropin AQ

Location

Maternal and Child Health Hospital of Anhui province
Hefei
Anhui
China

Status

Recruiting

Source

GeneScience Pharmaceuticals Co., Ltd.

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-11-30T15:45:22-0500

Clinical Trials [1106 Associated Clinical Trials listed on BioPortfolio]

Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)

The aim of this study is to assess the developmental patterns of lung function in children affected by growth hormone deficiency after one year of GH therapy.The assessment by specific qu...

Adult Growth Hormone Deficiency and Cardiovascular Risk

This protocol will assess the cardiovascular risk associated with growth hormone deficiency in adults. We will use multiple modalities to assess risk for heart attacks or strokes includin...

Diagnosing Adult Growth Hormone Deficiency

The purpose of this study was to validate the growth hormone releasing hormone (GHRH) plus arginine (GHRH+arg) stimulation test and it´s cut-off limits for diagnosis of adult growth hormo...

Treatment of Adults With Growth Hormone Deficiency

The purpose of this study is to evaluate efficacy and safety profile of a new weekly administered growth hormone preparation compared with placebo in adults with growth hormone deficiency.

Hormone Treatment in Growth Hormone and Testosterone Deficient Patients

Growth hormone and gonadotropin deficiency after brain injury (TBI, ischemic stroke, SAH): the effects of hormone replacement on cognition, quality of life and body composition Randomized,...

PubMed Articles [11173 Associated PubMed Articles listed on BioPortfolio]

Long-Term Outcomes, Genetics, and Pituitary Morphology in Patients with Isolated Growth Hormone Deficiency and Multiple Pituitary Hormone Deficiencies: A Single-Centre Experience of Four Decades of Growth Hormone Replacement.

Growth hormone (GH) has been used to treat children with GH deficiency (GHD) since 1966.

Comparative pharmacokinetic and pharmacodynamic evaluation between a new biosimilar and reference recombinant human growth hormone.

To extend available dosing options in the treatment of growth hormone deficiency, a comparative pharmacokinetic and pharmacodynamic phase-1 clinical study involving subcutaneous administration of grow...

Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial.

To assess auxological and safety data for growth hormone (GH)-treated children with SHOX deficiency.

Oral delivery of human growth hormone: Preparation, characterization, and pharmacokinetics.

Daily subcutaneous injection of human growth hormone has been used for the treatment of growth hormone deficiency and growth failure but has led to poor patient compliance and renal toxicity. Thus, it...

Long-term safety and efficacy of Omnitrope(®) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study.

To report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope(®), a somatropin biosimilar to Genotropin(®), in Italian patients with growth hormone deficiency (G...

Medical and Biotech [MESH] Definitions

A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development.

A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.

An autosomal recessive disorder characterized by short stature, defective GROWTH HORMONE RECEPTOR, and failure to generate INSULIN-LIKE GROWTH FACTOR I by GROWTH HORMONE. Laron syndrome is not a form of primary pituitary dwarfism (GROWTH HORMONE DEFICIENCY DWARFISM) but the result of mutation of the human GHR gene on chromosome 5.

The biologically active fragment of human growth hormone-releasing factor, consisting of GHRH(1-29)-amide. This N-terminal sequence is identical in several mammalian species, such as human, pig, and cattle. It is used to diagnose or treat patients with GROWTH HORMONE deficiency.

A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.

More From BioPortfolio on "Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency"

Quick Search
Advertisement
 

Searches Linking to this Trial